# Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

> **NCT07670468** · PHASE1,PHASE2 · RECRUITING · sponsor: **LucasBio** · enrollment: 27 (estimated)

## Conditions studied

- BKV Infection
- EBV Infection
- CMV Infection

## Interventions

- **BIOLOGICAL:** LB-DTK-MV

## Key facts

- **NCT ID:** NCT07670468
- **Lead sponsor:** LucasBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2027-06-04
- **Final completion:** 2027-06-04
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670468, "Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07670468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*